Lutathera® – New Targeted Cancer Medicine Uses Radioactive Particles to Destroy Rare Cancer Cells

Lutathera® approved by European Commission for Patients with Advanced, Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)   Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the European Commission (EC) has approved…